ZIM LABORATORIES LIMITED’s Post

Happy #FDAFriday! A "Teaching Resource Guide" was released by the FDA as a toolkit to educate health care professionals about biologics, mainly focusing on biosimilars and interchangeable biosimilars. *Sarfaraz K. Niazi, PhD, provides clarity on the: - goals and objectives - 2 levels of learning - types of resources - additional FDA resources "This resource is critical for helping health care professionals engage in informed decision-making and patient education regarding biosimilars, which are increasingly important in modern health care. " https://lnkd.in/e8KvU6Jq

Clinical trials are crucial for global health and wellbeing, improved patient care, and prevention, diagnosis and effective treatment of diseases. At the forefront of all clinical research efforts are the researchers and allied professionals without whom none of the advances in healthcare would have been possible. Let us salute them today and always. #indiapharma #internationalclinicaltrialsday #indiacro #clinicaltrials #clinicalresearch #clinicaltrials #InternationalClinicalTrialsDay #ICTDay #clinicaltrialsday #pharmaceuticals #Biotech

New insights from #ESC2024 on managing severe hypertriglyceridaemia. 🌍🩺 Join experts Prof Gerald Watts & Prof Robert Rosenson to explore the latest strategies and practical steps for clinicians. Watch the series here 🔗 https://ow.ly/nQSj50Txgxw #CardioVascular #Healthcare #MedicalEducation Supported by an unrestricted educational grant from Arrowhead Pharmaceuticals

💊 October 2024's Top-Searched Drugs on DRUGDOCS®   In October 2024, the following drugs were the top searches on DRUGDOCS®, highlighting key areas of interest for healthcare professionals:   🔹 #Jubbonti® https://lnkd.in/e_t4_maK 🔹 #Amtagvi® https://lnkd.in/eZ7e2US9 🔹 #Cobenfy® https://lnkd.in/efPZ7tGM   At DRUGDOCS®, healthcare professionals have direct access to a comprehensive, evidence-based resource on each drug, systematically and meticulously compiled from the latest peer-reviewed studies. Our platform’s AI-generated summaries distil this evidence into concise, actionable insights, supporting informed and confident decision-making.   Discover how DRUGDOCS® is transforming evidence-based medicine; visit DRUGDOCS.com to learn more.

➡ Move Beyond Features and Discover the "So What" Benefits! Elevate your brand by uncovering the deeper "so what" benefits that differentiate you from the competition. Join our webinar on July 25th to learn how to go beyond basic features and truly connect with your audience. 🗓️ Date: July 25th, 2024 🕛 Time: 12:00 pm EST Register Now: https://lnkd.in/gBkhuziR #webinar #pharma #pharmamarketing #brand #brandstrategy #HCP #ZoomRx #biopharmawebinar #pharmastrategy #Lifescience #patients

Top 10 medical device companies in the world in 2024 Oct 25, 2024 The global medical devices market was valued at $518 bn in 2023. It is projected $886 billion by 2030. The rising prevalence of chronic diseases, coupled with an increase in surgical and diagnostic procedures, is driving significant growth. This surge is pushing companies to enhance, innovate, and create groundbreaking medical advancements at an exciting pace. #researchanddevelopment #innovation #medicaldevices #diagnostics #pharmaceuticals #healthcare #lifesciences #biotechnology

🎧 𝗡𝗲𝘄 𝗣𝗼𝗱𝗰𝗮𝘀𝘁 𝗔𝗹𝗲𝗿𝘁! Are the drug interaction tools you trust giving consistent answers? What happens when the tools we rely on for safe prescribing don’t align? In this episode, Dr. David Burger discussed a study by Dr. Massimo Carollo and Prof. Gianluca Trifirò, uncovering surprising inconsistencies among various drug interaction checkers (ICs) when evaluating interactions involving widely-used proton pump inhibitors (PPIs). Key topics: 🔍 How different ICs identify and classify potential interactions with PPIs. 🔍 Discrepancies between IC data and official product summaries, and how this impacts clinical decisions. 🔍 Why it’s crucial to consult multiple sources, especially for complex regimens. 🔗 Listen now: https://amededu.co/4fCfBQK #DDIofTheMonth #DrugInteractions #PatientSafety #Pharmacology #DDI #ElderlyPatients #MedicationSafety #DigitalHealthPodcast #HealthcarePodcast

Biosimilars are emerging as a transformative force in healthcare, reshaping the way we approach and access medical treatments. They are reducing costs and improving access to vital treatments all over the world. Read more about how biosimilars are reshaping medicine in our latest blog here: https://lnkd.in/eivU2G7t #blog #medicine #biosimilars #pharma #generics

https://lnkd.in/eQaiFzEw Key Insights: • The Efemoral Vascular Scaffold System (EVSS) introduces a novel approach to treating peripheral arterial occlusive disease (PAOD) by addressing specific anatomical challenges and complex biomechanics of patients with athero-occlusive disease in the leg Visit MedicoInsights to explore key insights #HealthcareNews #drugs #StayInformed #MedicalNews #drugapproval #HealthTrends #Insights #HealthIndustry #HealthInnovation #medicaldevices #breakthrough #devicedesignation #HealthcareAnalytics #NewsUpdate #HealthcareNetworking #pharma #pharmaceuticals #pharmanews #pharmaindustry #pharmainnovation #update #medicoinsights

This slide from this week's Festival of Biologics USA highlighted the dysfunction in our healthcare system. Despite having 8 biosimilar competitors, Humira still holds a whopping 97% of the market share. However, Kaiser Permanente physicians, pharmacists, and patients are setting a great example with over 90% adoption of the adalimumab biosimilar. This is great news for patients as biosimilar competition lowers the cost of biologics, making them more affordable. According to IQVIA, biosimilar use could save our nation a staggering $180 billion in healthcare costs by 2027. Let's hope the US can realize these savings while keeping more people healthy. #healthcare #biosimilar #affordablemedicine #healthcosts #KaiserPermanente